Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.90 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.90 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | HTR6 | P50406 | 1/20 | 0.70 |
| ▸ | ESRRG | P62508 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.64 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9098770 | 1.00 | ESR1 (0.90) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL906293 | 1.00 | ESR1 (0.90) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL28404807 | 0.95 | CYP19A1 (1.00) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL24302096 | 0.95 | CYP19A1 (1.00) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL22995790 | 0.95 | CYP19A1 (1.00) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL17506000 | 0.91 | CYP19A1 (0.78) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL19011568 | 0.90 | HTR6 (0.75) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| SCHEMBL17915615 | 0.90 | HTR6 (0.75) | ESR1CYP19A1ESR2CYP3A4LMNA | |
| Ospemifene SCHEMBL948118 | 0.87 | LMNA (0.71) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL9098639 | 0.87 | CYP19A1 (0.72) | ESR1CYP19A1ESR2CYP3A4ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | THE PENN STATE RESEARCH FOUNDATION | 2017-08-03 | — | — | US | disclosed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | CYP46A1, GSTA2, GSTA1 | ESR1 1247/4885CYP19A1 34/4885ESR2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.